Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$52.15

0.23 (0.44%)

, JNJ

Johnson & Johnson

$115.31

-0.35 (-0.30%)

07:01
12/22/16
12/22
07:01
12/22/16
07:01

Ionis earns milestone payment from Janssen for advancing new program under deal

Ionis Pharmaceuticals (IONS) announced that it has earned $5M milestone payment from Janssen Biotech (JNJ) associated with the validation of an undisclosed target to treat patients with a gastrointestinal autoimmune disease. Under the collaboration, Ionis and Janssen will continue to evaluate the target with the goal of advancing an antisense drug into development. Under the terms of the agreement, which covers three programs, Ionis is eligible to receive nearly $800M in development, regulatory and sales milestone payments and license fees. In addition, Ionis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized.

IONS

Ionis Pharmaceuticals

$52.15

0.23 (0.44%)

JNJ

Johnson & Johnson

$115.31

-0.35 (-0.30%)

  • 05

    Jan

  • 09

    Jan

  • 01

    Feb

IONS Ionis Pharmaceuticals
$52.15

0.23 (0.44%)

11/07/16
JPMS
11/07/16
NO CHANGE
JPMS
Neutral
JPMorgan still views Ionis as fairly valued
JPMorgan analyst Jessica Fye believes the data today continue to "derisk and solidify" Spinraza's clinical profile. The analyst, however, thinks it will be difficult to lift the overhang around platelet adverse events. She continues to view Ionis Pharmaceuticals as fairly valued and keeps a Neutral rating on the shares. Ionis is up 18% to $32.10 in afternoon trading.
12/20/16
BMOC
12/20/16
NO CHANGE
BMOC
Ionis Pharmaceuticals price target raised to $61 from $48 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Ionis after positive Phase III data for its Volanesorsen drug was reported. The analyst says the data improves the chances of success for two upcoming pivotal studies, and Kim thinks that the risk/reward ratio for the company's January 5 Analyst Day is positive. Kim keeps an Outperform rating on the shares.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Gilead buying Alexion tops Piper's potential events in 2017
Piper Jaffray healthcare analysts, led by Joshua Schimmer, laid out 17 potential surprise or provocative events for Biopharma in 2017. Their potential outcomes and events are led Gilead (GILD) acquiring Alexion (ALXN) and a President Donald Trump tweeting about the price of Biogen and Ionis Pharmaceuticals' (IONS) Spinraza. Other potential events Piper sees is a "massively dilutive" equity recapitalization for Valeant (VRX) and a failure for Seattle Genetics' (SGEN) ECHELON trial. The firm also sees the potential for Teva cleaning house and bringing in a non-Israeli CEO.
JNJ Johnson & Johnson
$115.31

-0.35 (-0.30%)

11/29/16
LEHM
11/29/16
DOWNGRADE
Target $125
LEHM
Equal Weight
Johnson & Johnson downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Johnson & Johnson to Equal Weight and lowered its price target to $125 from $130. The analyst said risk/reward is less compelling and said shares could become a source of funds due to Remicade biosimilar risk, slowing med tech utilization, reduced pipeline impact, and a move away from defensive names.
11/29/16
11/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
On The Fly: Top five analyst downgrades: 1. Wendy's (WEN) downgraded to Neutral from Buy at Goldman with analyst Karen Holthouse citing valuation with the stock up 23% over the past month. 2. SAIC (SAIC) downgraded to Neutral from Buy at Citi with analyst Jonathan Raviv citing the recent rally in the shares and some overhang from the pending contract transition. 3. BioMarin (BMRN), Johnson & Johnson (JNJ), and Vertex (VRTX) were downgraded to Equal Weight from Overweight at Barclays. 4. Nivalis Therapeutics (NVLS) downgraded to Market Perform Raymond James, to Hold from Buy at Stifel, to Market Perform from Outperform at Cowen, and to Neutral from Outperform at Baird. 5. U.S. Steel (X) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/16
GSCO
12/02/16
NO CHANGE
Target $82
GSCO
Buy
Jardiance CV death risk reduction indication a positive for Lilly, says Goldman
Goldman Sachs analyst Jami Rubin said his estimate, and the current consensus estimate, for Jardiance sales assumed that Eli Lilly (LLY) would get a new indication for Jardiance to reduce the risk of cardiovascular death in type 2 diabetes patients, but he still views the news as positive for sentiment given some investor nervousness and the recent solanezumab disappointment. The indication differentiates Jardiance from Johnson & Johnson's (JNJ) Invokana and AstraZeneca's (AZN) Farxiga, adds Rubin, who has a Buy rating and $82 price target on Lilly shares.
12/20/16
UBSW
12/20/16
NO CHANGE
UBSW
Neutral
Sanofi strategy for Actelion acquisition not clear, says UBS
UBS analyst Jack Scannell provided thoughts on the potential Sanofi (SNY) acquisition of Actelion (ALIOY) after Johnson & Johnson (JNJ) dropped out of the bidding. The reason JNJ backed out was it did not believe it could enhance shareholder value with the deal and Scannell believes the same could be said for Sanofi. He does see a path to accretive earnings in a cash and stock deal and if Sanofi could delever from its EBITDA level within a year. Scannell, however, said the strategic reasons for the deal remain unclear and could raise questions about Sanofi's overall strategy.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

11:16
08/16/17
08/16
11:16
08/16/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$20.23

-0.025 (-0.12%)

11:15
08/16/17
08/16
11:15
08/16/17
11:15
Recommendations
MSG Networks analyst commentary  »

MSG Networks valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

11:10
08/16/17
08/16
11:10
08/16/17
11:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

URBN

Urban Outfitters

$16.82

-0.91 (-5.13%)

11:00
08/16/17
08/16
11:00
08/16/17
11:00
Options
Active trading in Urban Outfitters as shares rally »

Active trading in Urban…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$63.45

-0.06 (-0.09%)

, XLU

Utilities SPDR

$54.43

0.075 (0.14%)

10:59
08/16/17
08/16
10:59
08/16/17
10:59
Technical Analysis
Technical View: S&P 500 at highs of day as mid-session approaches »

The S&P 500 (SPX) was…

XLE

Energy Select Sector SPDR

$63.45

-0.06 (-0.09%)

XLU

Utilities SPDR

$54.43

0.075 (0.14%)

SPY

SPDR S&P 500 ETF Trust

$247.35

0.84 (0.34%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
08/16/17
08/16
10:55
08/16/17
10:55
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

UNP

Union Pacific

$105.65

0.8 (0.76%)

10:54
08/16/17
08/16
10:54
08/16/17
10:54
Hot Stocks
Union Pacific to recognize $90M charge in Q3 on staff reorganization plan »

On August 16, Union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 06

    Sep

URBN

Urban Outfitters

$16.82

-0.91 (-5.13%)

, GPS

Gap

$22.59

0.52 (2.36%)

10:51
08/16/17
08/16
10:51
08/16/17
10:51
Hot Stocks
Urban Outfitters jumps after reporting earnings, sales beat »

Shares of Urban…

URBN

Urban Outfitters

$16.82

-0.91 (-5.13%)

GPS

Gap

$22.59

0.52 (2.36%)

ANF

Abercrombie & Fitch

$9.66

0.29 (3.10%)

AEO

American Eagle

$11.33

0.41 (3.75%)

ZUMZ

Zumiez

$11.75

-0.35 (-2.89%)

BEBE

bebe stores

$5.06

-0.29 (-5.42%)

JCP

J.C. Penney

KSS

Kohl's

$38.37

0.24 (0.63%)

M

Macy's

$20.50

0.21 (1.04%)

JWN

Nordstrom

$44.64

-0.02 (-0.04%)

SHLD

Sears

$8.63

0.02 (0.23%)

AMZN

Amazon.com

$982.74

-0.56 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 17

    Aug

  • 18

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 28

    Sep

  • 09

    Nov

VALE

Vale

$9.94

0.16 (1.64%)

10:50
08/16/17
08/16
10:50
08/16/17
10:50
Options
9.8K VALE Aug - Sep 10 call spreads bought for 30c »

9.8K VALE Aug - Sep 10…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:41
08/16/17
08/16
10:41
08/16/17
10:41
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts provide a…

FCX

Freeport McMoRan

$14.68

0.71 (5.08%)

10:40
08/16/17
08/16
10:40
08/16/17
10:40
Options
Flurry of activity in Freeport McMoran as shares break a downtrend »

Flurry of activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$922.22

-0.45 (-0.05%)

, GOOGL

Alphabet Class A

$938.08

-0.85 (-0.09%)

10:38
08/16/17
08/16
10:38
08/16/17
10:38
Initiation
On The Fly: Top analyst initiations »

Catch up on today's…click here.

GOOG

Alphabet

$922.22

-0.45 (-0.05%)

GOOGL

Alphabet Class A

$938.08

-0.85 (-0.09%)

FB

Facebook

$171.00

0.25 (0.15%)

GDDY

GoDaddy

$41.95

0.26 (0.62%)

WIX

Wix.com

$58.15

-2.35 (-3.88%)

BABA

Alibaba

$158.93

1.18 (0.75%)

AMZN

Amazon.com

$982.74

-0.56 (-0.06%)

PCLN

Priceline

$1,860.84

-13.115 (-0.70%)

SNAP

Snap

$13.10

0.36 (2.83%)

TWTR

Twitter

$16.18

0.23 (1.44%)

EBAY

eBay

$35.25

0.05 (0.14%)

HDS

HD Supply

$31.01

-0.58 (-1.84%)

SHLO

Shiloh Industries

$7.68

-0.33 (-4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 17

    Aug

  • 18

    Aug

  • 21

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 28

    Aug

  • 29

    Aug

  • 30

    Aug

  • 05

    Sep

  • 07

    Sep

  • 12

    Sep

  • 13

    Sep

DKS

Dick's Sporting

$27.57

0.7 (2.61%)

, TEVA

Teva

$17.78

-0.19 (-1.06%)

10:37
08/16/17
08/16
10:37
08/16/17
10:37
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

DKS

Dick's Sporting

$27.57

0.7 (2.61%)

TEVA

Teva

$17.78

-0.19 (-1.06%)

AAP

Advance Auto Parts

$88.57

1.49 (1.71%)

SLG

SL Green Realty

$99.52

0.05 (0.05%)

KRC

Kilroy Realty

$69.90

-0.07 (-0.10%)

GPT

Gramercy Property Trust

$29.15

-0.32 (-1.09%)

CBI

CB&I

$10.59

-0.605 (-5.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 23

    Aug

  • 30

    Aug

HD

Home Depot

$152.68

2.5128 (1.67%)

, MYL

Mylan

$30.13

0.5 (1.69%)

10:37
08/16/17
08/16
10:37
08/16/17
10:37
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

HD

Home Depot

$152.68

2.5128 (1.67%)

MYL

Mylan

$30.13

0.5 (1.69%)

BIIB

Biogen

$287.92

1.87 (0.65%)

ZION

Zions Bancorp

$45.13

0.14 (0.31%)

PAYX

Paychex

$55.59

0.67 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 03

    Sep

  • 08

    Sep

  • 12

    Sep

  • 09

    Oct

  • 30

    Oct

ADP

ADP

$111.58

1.89 (1.72%)

10:36
08/16/17
08/16
10:36
08/16/17
10:36
Conference/Events
Pershing Square Capital Management holds a teleconference »

Pershing discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

MYL

Mylan

$30.13

0.5 (1.69%)

, TEVA

Teva

$17.67

-0.3041 (-1.69%)

10:33
08/16/17
08/16
10:33
08/16/17
10:33
Hot Stocks
Citi views Mylan as best positioned in generic ratings shift »

Citi this morning shifted…

MYL

Mylan

$30.13

0.5 (1.69%)

TEVA

Teva

$17.67

-0.3041 (-1.69%)

ENDP

Endo

$8.14

0.52 (6.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 03

    Sep

  • 08

    Sep

  • 09

    Oct

XGTI

xG Technology

$2.21

-0.08 (-3.49%)

10:32
08/16/17
08/16
10:32
08/16/17
10:32
Syndicate
xG Technology announces $3.2M registered direct offering, private placement »

xG Technology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

10:32
08/16/17
08/16
10:32
08/16/17
10:32
General news
Crude Inventories for the week of August 11 »

Crude inventories 8.94M…

EVOL

Evolving Systems

$4.90

-0.2 (-3.92%)

10:31
08/16/17
08/16
10:31
08/16/17
10:31
Hot Stocks
Evolving Systems to acquire Lumata; terms not disclosed »

Evolving Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$71.85

0.045 (0.06%)

10:30
08/16/17
08/16
10:30
08/16/17
10:30
Options
4.5K Colgate Aug - Sep 72.5 put spreads sold at 76c »

4.5K Colgate Aug - Sep…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEFF

Neff

$24.80

-1.35 (-5.16%)

, HEES

H&E Equipment

$21.09

0.16 (0.76%)

10:29
08/16/17
08/16
10:29
08/16/17
10:29
Hot Stocks
Breaking Hot Stocks news story on Neff, H&E Equipment »

Neff says to move forward…

NEFF

Neff

$24.80

-1.35 (-5.16%)

HEES

H&E Equipment

$21.09

0.16 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAP

Advance Auto Parts

$88.96

1.875 (2.15%)

10:28
08/16/17
08/16
10:28
08/16/17
10:28
Recommendations
Advance Auto Parts analyst commentary  »

Advance Auto Parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEFF

Neff

$24.78

-1.375 (-5.26%)

, HEES

H&E Equipment

$21.09

0.16 (0.76%)

10:28
08/16/17
08/16
10:28
08/16/17
10:28
Hot Stocks
Neff: H&E Equipment won't submit revised proposal to acquire company »

Neff Corporation (NEFF)…

NEFF

Neff

$24.78

-1.375 (-5.26%)

HEES

H&E Equipment

$21.09

0.16 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$83.02

0.58 (0.70%)

10:25
08/16/17
08/16
10:25
08/16/17
10:25
Conference/Events
Nevro has conference call hosted by Leerink »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 21

    Aug

BMY

Bristol-Myers

$57.39

-0.48 (-0.83%)

, EXEL

Exelixis

$26.91

0.17 (0.64%)

10:22
08/16/17
08/16
10:22
08/16/17
10:22
Hot Stocks
Analysts bullish on Exelixis after rival faces setback in kidney cancer trial »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$57.39

-0.48 (-0.83%)

EXEL

Exelixis

$26.91

0.17 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 08

    Sep

  • 11

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.